Costly drug may save money in severe childbirth bleeding, but study cut short
NCT ID NCT02900690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the costs of treating severe postpartum hemorrhage with a drug called NovoSeven compared to standard care. Researchers wanted to see if the higher drug cost could be offset by avoiding expensive procedures. The trial was terminated early and included 84 women with severe bleeding after childbirth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant activated factor VII (NovoSeven)
What this could lead to
If successful, it could show whether using NovoSeven is cost-effective for severe bleeding after childbirth, potentially guiding hospital policies.
What could go wrong
The trial was terminated early, so results are limited. It only looked at costs, not whether NovoSeven improves survival or reduces complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST PARTUM HAEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes
Nîmes, Gard, 30029, France